Bio-Path Holdings Q2 EPS $(0.53) Misses $(0.44) Estimate, R&D $3.1M; Co. Had Cash Of $3.4M As Of Jun. 30
Portfolio Pulse from Benzinga Newsdesk
Bio-Path Holdings reported Q2 losses of $(0.42) per share, beating the analyst consensus estimate of $(0.44) by 4.55%. The company had cash of $3.4M as of June 30. The EPS is unchanged from the same period last year.

August 15, 2023 | 11:01 am
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Bio-Path Holdings reported better than expected Q2 earnings, which could positively impact the stock in the short term.
Bio-Path Holdings reported a smaller loss than expected for Q2, which is generally seen as positive news by investors. This could lead to increased buying pressure, potentially driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100